ClinicalTrials.gg
CompletedNCT06646419BRIDGE-COPDUpdated Oct 9, 2026

Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle

An observational study in COPD, sponsored by AstraZeneca. Completed at 37 sites in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Observational

How we know

Updated Oct 6, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,368
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
38th of 89
1,368 · median 976
Started
2024
with 16 others
Observational
90 of 284
7 open now
Registered
265th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 38th largest by enrollment of the 89 observational ones that give a count, is one of 17 that started in 2024, is one of 90 observational ones, and was the 265th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

This is a cluster randomized interventional study. Intervention is implemented at a hospital level and will change overall daily practice. 36 county level hospitals are r an domized to the intervention group or control group at the ratio of 2:1 . Total subjects is 1368 and a size of 38 per hospital .

Read the detailed description

The intervention is composed of 3 active components: 1) education on guideline led disease knowledge and transition bundle led management pathway, 2) standardized transition bundle implementation, 3) clinical audit.

Education begins at nearly 4 weeks before first subject in and keep learning every 4 weeks.Standardized transition bundle will be implemented once the first round education is completed. Clinical audit takes up after first subject enrolled and implemented every 12 weeks.The control group will maintain the current usual care practice. Eligible patients will be recruited in both groups and will be followed up every 12 weeks for 48 weeks.

Eligible consented patients will be enrolled consecutively to minimize selection bias. In order to achieve the purpose of continuous enrollment, all patients who visit the outpatient clinic,emergency room, and hospitalized due to exacerbation of COPD will be screened, including newly diagnosed patients or those who have bee n treated.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population in this study are in the hospital exacerbation COPD patients with high risk of future exacerbation. Exacerbation COPD is defined as an event characterized by dyspnea and/or cough and sputum that worsen over \<14 days. Exacerbation of COPD are often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insults to the lungs.. Screening occurs when AECOPD identified in emergency room, respiratory outpatient clinic or inpatient department. Enrolment occurs when AECOPD treated for several days entering recovery period and transferring to home.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed (post- bronchodilator /FVC \< 0.7)
  • 40\~80 years
  • CAT≥10
  • At least two moderate or at least one severe exacerbation history in past 1 year
  • Able to sign

Exclusion criteria

Exclusion Criteria:

  • Continuous triple inhalation therapy for ≥6 months at baseline (include single inhaler and multiple inhalers)
  • Stable (symptom such as cough, sputum and shortness of breath are mild or stable, clinical condition has basically returned to pre-exacerbation)
  • Comorbidities require/contraindicate long-term use of treatment: asthma, interstitial lung disease, sarcoidosis, cystic fibrosis, active tuberculosis recurrent aspiration pneumonia ect.
  • Serious comorbidities threaten to life expected survival time no more than 1 year: severe heart disease, severe chronic liver, severe kidney disease, cerebrovascular disease with long-term bed rest and malignant tumours ect.
  • Not living in the healthcare area
  • Patients currently participating in any other interventional studies
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,368 participants (actual)
Patient registry
No

Groups and cohorts

  • Intervention group

    Intervention is implemented at a hospital level and will change overall daily practice. The intervention is composed of 3 active components: 1) education on guideline led disease knowledge and transition bundle led management pathway, 2) standardized transition bundle implementation, 3) clinical audit.Education begins at nearly 4 weeks before first subject in and keep learning every 4 weeks. Standardized transition bundle will be implemented once the first round education is completed. Clinical audit takes up after first subject enrolled and implemented every 12 weeks.

  • Control group

    The control group will maintain the current usual care practice.

06

What researchers measure

Primary outcomes

  1. Time to CID.

    To evaluate the the impact of implementation and audit of transition bundle on clinically important deterioration (CID).

    Time frame: week0-week48

Secondary outcomes

  1. Proportion of patients received long-acting maintenance inhalation with the percentage of days covered (PDC) ≥70%.

    To evaluate the the impact of implementation and audit of transition bundle on treatment compliance.

    Time frame: week 12, 24, 36 and 48

  2. Inhalation therapy consistency rate with guideline.

    To evaluate the the impact of implementation and audit of transition bundle on treatment compliance.

    Time frame: week 12, 24, 36 and 48

  3. Inhaler device compliance,measured by the score of Test of the adherence to inhalers( TAI ) questionnare.

    To evaluate the the impact of implementation and audit of transition bundle on treatment compliance.

    Time frame: week 24 and 48

  4. Correct operation rate of inhalation device.

    To evaluate the the impact of implementation and audit of transition bundle on treatment compliance.

    Time frame: week 24 and 48

  5. Patient satisfaction rate with treatment.

    To evaluate the the impact of implementation and audit of transition bundle on treatment satisfaction.

    Time frame: week 24 and 48

  6. Disease knowledge score of patients.

    To evaluate the the impact of implementation and audit of transition bundle on disease knowledge.

    Time frame: week 24 and 48

  7. Proportion of patients received different categories of long-acting maintenance inhalation.

    To evaluate the the impact of implementation and audit of transition bundle on treatment pattern.

    Time frame: week 12, 24,36 and 48

  8. Rate of moderate or severe exacerbation.

    To evaluate the the impact of implementation and audit of transition bundle on exacerbation.

    Time frame: week 12, 24 and 48

  9. Rate of severe exacerbation.

    To evaluate the the impact of implementation and audit of transition bundle on exacerbation.

    Time frame: week 12, 24 and 48

  10. Rate of cardiovascular events.

    To evaluate the the impact of implementation and audit of transition bundle on cardiovascular events.

    Time frame: week 12, 24 and 48

  11. Change of CAT score.

    To evaluate the the impact of implementation and audit of transition bundle on quality of life.

    Time frame: week 0 to week 48

  12. Percentage change of trough FEV1 and MMEF.

    To evaluate the the impact of implementation and audit of transition bundle on PFT.

    Time frame: week 0 to week 48

07

Study locations

37 sites
  • Research Site
    Anyang, China
  • Research Site
    Baise City, China
  • Research Site
    Beijing, China
  • Research Site
    Bijie, China
  • Research Site
    Changsha, China
  • Research Site
    Chenzhou, China
  • Research Site
    Chifeng, China
  • Research Site
    Chuzhou, China
  • Research Site
    Deyang, China
  • Research Site
    Fuyang, China
  • Research Site
    Hangzhou, China
  • Research Site
    Hefei, China
  • Research Site
    Jieyang, China
  • Research Site
    Jining, China
  • Research Site
    Jiujiang, China
  • Research Site
    Kaiyuan, China
  • Research Site
    Langfang, China
  • Research Site
    Langzhong, China
  • Research Site
    Leping, China
  • Research Site
    Nanchang, China
  • Research Site
    Nanchong, China
  • Research Site
    Neijiang, China
  • Research Site
    Qiannan, China
  • Research Site
    Qujing, China
  • Research Site
    Sanmenxia, China
  • Research Site
    Shaoyang, China
  • Research Site
    Suzhou, China
  • Research Site
    Tengzhou, China
  • Research Site
    Tieling, China
  • Research Site
    Wenzhou, China
  • Research Site
    Xiangtan, China
  • Research Site
    Xiaogan, China
  • Research Site
    Xinyang, China
  • Research Site
    Yancheng, China
  • Research Site
    Yichang, China
  • Research Site
    Yuling, China
  • Research Site
    Zaoyang, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' , indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Sep 2026, 22 months.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 22 months is close to that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2024
First posted
Oct 17, 2024
StartActual
Nov 13, 2024
Primary completionActual
Sep 21, 2026was Aug 2026
CompletionActual
Sep 21, 2026was Aug 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Primary completion
Aug 31, 2026→Sep 21, 2026 (actual)
Oct 6, 2026
Study completion
Aug 31, 2026→Sep 21, 2026 (actual)
Oct 6, 2026
Show all 2 updates
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 6, 2026
    Active, not recruiting→Completed
    Primary completion Aug 31, 2026→Sep 21, 2026 (now actual)
    Study completion Aug 31, 2026→Sep 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06646419
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Nov 13, 2024
Primary completion
Sep 21, 2026
Completion
Sep 21, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion